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S UMMARY
Suppose that we are interested in using new biomarkers to improve prediction or diagnosis of the patient’s
clinical phenotype in addition to the conventional markers. The incremental value from the new markers
is typically assessed by averaging across patients in the entire population of interest. However, when measuring the new markers is costly or invasive, an overall improvement does not justify measuring the new
markers in all patients. A more practical strategy is to utilize the patient’s conventional markers to decide
whether the new markers are needed for improving prediction of his/her health outcomes. In this article,
we propose inference procedures for the incremental values of new markers across various subgroups of
patients classified by the conventional markers. The resulting point and interval estimates can be quite
useful for medical decision makers seeking to balance the predictive or diagnostic value of new markers
against their associated cost and risk. Our proposals are theoretically justified and illustrated empirically
with two real examples.
Keywords: Biomarker, Clinical Outcome, Diagnosis, Incremental Prediction Accuracy, K-fold Cross Validation, Prediction, Subgroup Analysis

1. I NTRODUCTION
Biological and technological advances continually generate promising new biomarkers with the potential to improve medical care by providing more accurate, personalized predictions of health outcomes
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and diagnoses of clinical phenotypes. However, extensive use of new markers may provide only negligible improvements in prediction or diagnosis, while subjecting patients to additional risks and costs. It
is therefore important to develop statistical methods that can quantify for individual patients the value
of new markers over conventional ones, especially when measuring these markers is costly or invasive.
As an example, in a recent study, the incremental values from ten new biomarkers for prediction of first
major cardiovascular events and death in a Framingham Study cohort were examined extensively (Wang
and others, 2006). There were 3209 participants in the study. They were followed for a median of 7.4
years, during which 207 participants died and 169 had a first major cardiovascular event. Based on various prediction precision criteria, the study team found that the ten contemporary biomarkers added only
moderate overall predictive value to the classical risk factors. In contrast, other investigators studying
different populations with different prediction precision measures demonstrated that certain biomarkers
provide clinically useful prognostic information on top of, for example, the traditional Framingham risk
score for heart diseases (Ridker and others, 2002, 2007; Blumenthal and others, 2007).
Despite these often controversial findings in the literature, clinical practitioners would generally not
change their recommendation for the patient’s care with the extra marker information if the patient, for
example, has either high or very low conventional risk score. Therefore, a practically important question is
how to systematically identify patients who would benefit from the additional markers instead of evaluating these markers based only on their average incremental value across the entire population (D’Agostino
, 2006). In this article, we propose procedures to estimate the incremental values of new markers for diagnosis or prediction in various subgroups of patients classified by conventional markers. These, coupled
with the sampling variations of the estimates, provide a useful tool for researchers and practitioners to
decide when, after observing the conventional risk factors, the new markers are needed. In Section 2, we
describe in detail the new procedure and provide theoretical justification. In Section 3, we illustrate our
methods with two examples, one with a continuous response and the other with a binary outcome.
There are quite a few procedures in the literature for evaluating the over-all incremental value of new
markers for an entire population of interest. For example, Pepe and others (2004) compared the ROC
curves among models with and without an additional marker. Recently, Tian and others (2007) and Uno
and others (2007) proposed robust inference procedures for evaluating prediction rules. Prediction or
diagnostic precision measures, which may be used for comparing different prediction procedures, have
also been proposed and utilized, for example, by Brier (1950), Breiman and others (1984), Speigelhalter
(1986), Korn and Simon (1990), McLachlan (1992), Mittlböck and Schemper (1996), Ripley (1996),
Zhou and others (2002) and Pepe (2003).

2. E STIMATING S UBJECT-S PECIFIC P REDICTION E RROR BASED ON R ISK S CORE C ONSTRUCTED
FROM C ONVENTIONAL M ARKERS
Let Y be a continuous or binary response variable, U be the set of its conventional marker values, and
V be the corresponding counterpart from the new markers. Our data consist of n independent copies
{(Yi , Ui , Vi ), i = 1, · · · , n} from (Y, U, V ). The problem is how to use the data to identify future subjects
via U, which would benefit from the new markers for better prediction of their responses Y . Suppose that
there are no well-established rules for classifying subjects based on U for predicting Y . First, we may
estimate a center value of Y given U nonparametrically and use this estimate to construct a predictor
for Y . We then estimate the average prediction error, the “distance” between the observed response and
its predicted value over all subjects which have the same marker value U . Next, we estimate the center
of Y given U and V, and estimate the corresponding average prediction error conditional only on U .
Inferences about the improvement from the new markers can be made via these functional estimates over
U . Unfortunately, in general, we can only construct nonparametric functional estimates, which behave
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reasonably well, when the dimension of U is very small and the sample size n is quite large.
A practically feasible alternative to handle this problem is to consider a parametric or semi-parametric
approach. To this end, let X be a p-dimensional vector, a function of U . Assume that the conditional mean
of Y given U can be approximated by the following working model
E(Y | U ) = g1 (β 0 X),

(2.1)

where g1 (·) is a smooth, strictly increasing, known function and β is an unknown vector of parameters.
Note that the first component of X is one. In this article, we deal with the interesting and challenging case
that β 0 X is a continuous variable.
To estimate the regression parameters for model (2.1) which, most likely, is an approximation to the
true conditional mean of Y given U, one may use the estimator βb based on the simple estimating function
S1 (β) =

n
X

Xi {Yi − g1 (β 0 Xi )} ,

(2.2)

i=1

where {(Yi , Xi ), i = 1, · · · , n} are n-independent copies of (Y, X) (Tian and others, 2007). Note that
even when (2.1) is not the true model, βb converges to a constant vector β0 , as n → ∞. It is not clear,
however, that other standard estimators for β in (2.1) would be convergent as n gets large.
Now, consider a future independent subject with (Y, X) = (Y 0 , X 0 ). For a given β in (2.1), let
Yb1 (β 0 X 0 ) be the predictor for Y 0 . For example, when Y 0 is continuous, one may let Yb1 (β 0 X 0 ) =
g1 (β 0 X 0 ) and when Y 0 is binary, one may predict Y 0 by a binary variable Yb1 (β 0 X 0 ) = I{g1 (β 0 X 0 ) >
0.5}, where I(·) is the indicator function. Other prediction rules for the binary case will be discussed
in the Example Section. To evaluate the performance of Yb1 (βb0 X 0 ), we first need to quantify its prediction accuracy based on a “distance” between the true Y 0 and the predicted Yb1 (βb0 X 0 ), denoted by
D{Y 0 , Yb1 (βb0 X 0 )}. For example, one may let D(a, b) = |a − b|. For the binary case, this distance function is simply I(a 6= b). Other choices of distance functions will be discussed in Section 3.
Next, since clinical practitioners almost always group subjects with a “risk scoring system” for medical decision making, we consider an average prediction error over a set of X’s which have “similar”
g1 (βb0 X) to evaluate Yb1 (·). To be specific, let Jz = (cz , dz ) be a data-independent interval centered about
z, where z ranges over a set of possible values of g1 (β00 X). The average prediction error over Jz is
D1? (z) = E[D{Y 0 , Yb1 (βb0 X 0 )}| g1 (βb0 X 0 ) ∈ Jz ], where the conditional expectation is taken with respect
b As n → ∞, D? (z) converges to
to (Y 0 , X 0 ) and β.
1
h
i
D1 (z) = E D{Y 0 , Yb1 (β00 X 0 )}| g1 (β00 X 0 ) ∈ Jz ,
(2.3)
where the expectation is taken with respect to (Y 0 , X 0 ). As a process of z, this moving average process
{D1 (z)} provides a performance profile of Yb1 (·) over all possible values of g1 (β00 X). The choices of Jz
are discussed via two examples in the next section.
Now, let W be a q × 1 vector, a function of U and V . Assume that a working model for the conditional
mean of Y given U and V is
E(Y | U, V ) = g2 (θ0 W ),
(2.4)
where g2 (·) is a smooth, strictly increasing, known function and θ is an unknown vector of parameters.
The first component of W is one. Again, we assume that g2 (θ0 W ) is a continuous variable. Let θb be the
estimator for θ obtained from the following simple estimating function
S2 (θ) =

n
X

Wi {Yi − g2 (θ0 Wi )} ,

(2.5)

i=1
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b Consider a future
where Wi , i = 1, · · · , n, are n independent copies of W . Let θ0 be the limit of θ.
0
0
0
0
0
b
independent (Y, X, W ) = (Y , X , W ). Let Y2 (θ W ) be the predictor constructed from (2.4) with
parameter value θ, the counterpart of Yb1 (β 0 X 0 ). For the aforementioned interval Jz , let the average prediction error for Yb2 (·) over Jz be
¯
h
i
¯
D2 (z) = E D{Y 0 , Yb2 (θ00 W 0 )}¯ g1 (β00 X 0 ) ∈ Jz ,
(2.6)
where the expectation is taken with respect to (Y 0 , X 0 , W 0 ). Then, as a process in z,
∆(z) = D1 (z) − D2 (z)

(2.7)

provides a global picture for identifying subgroups of patients who would benefit from the additional
markers.
To estimate D1 (z) and D2 (z), one may use
Pn
b0
b b0
i , Y1 (β Xi )}I{g1 (β Xi ) ∈ Jz }
b1 (z) = i=1 D{Y
D
(2.8)
Pn
b0
i=1 I{g1 (β Xi ) ∈ Jz }
and
b2 (z) =
D

Pn
i=1

D{Yi , Yb2 (θb0 Wi )}I{g1 (βb0 Xi ) ∈ Jz }
,
Pn
b0
i=1 I{g1 (β Xi ) ∈ Jz }

(2.9)

b
b1 (z) − D
b2 (z) to estimate ∆(z). In Appendix A, we show that with
respectively. We then let ∆(z)
=D
the distance function D(a, b) = |a − b| or a function thereof, the above three estimators are uniformly
consistent over an interval Ω consisting of all z’s whose intervals Jz ’s are properly in the support of
g1 (β00 X). Similar arguments may be used for cases with other distance functions.
To make further inferences about the added value from the new markers for predicting the response,
c1 (z) = n1/2 {D
b1 (z) − D1 (z)},
in Appendix A, we show that the limiting distributions of the processes W
1/2
1/2
c2 (z) = n {D
b2 (z) − D2 (z)} and W(z)
c
b
W
= n {∆(z)
− ∆(z)}, are the same as those of the Gaussian processes W1∗ (z), W2∗ (z) and W ∗ (z), respectively, for z ∈ Ω. Here, realizations from these three
Gaussian processes (6.3), (6.4) and (6.5) given in Appendix A can be generated easily for any interval of
b 1 (z) and D
b 2 (z) are well-defined. In practice, one may not able to construct reasonably wellz, where D
b be a set of
behaved interval estimators for Dl (z), l = 1, 2, for z is the tail parts of Ω. To this end, let Ω
Pn
Pn
−1
0
−1
0
b
b
z such that Jz ⊂ [η1 , η2 ], where n
i=1 I{g(β Xi ) 6 η1 } > d1 , n
i=1 I{g(β Xi ) > η2 } > d2 ,
b
and d1 and d2 are given positive numbers. Then, with the above large sample approximations, for z ∈ Ω,
a (1 − α), 0 < α < 1, point-wise confidence interval for Dl (z), l = 1, 2, is
b l (z) ± ξα/2 σW ∗ (z) .
D
l

(2.10)

2
Here, σW
is the variance of the random variable Wl∗ (z) and ξα is the upper 100αth percentage point
∗
l (z)
b is
of the standard normal. Furthermore, a (1 − α) simultaneous confidence band for {Dl (z), z ∈ Ω}

b l (z) ± τlα σW ∗ (z) ,
D
l
where

(2.11)

¯
¯
n
o
¯ ∗
¯
pr supz∈Ω
b ¯Wl (z)/σWl∗ (z) ¯ < τlα > 1 − α.

b
To construct interval estimators for ∆(z), it is important to note that ∆(z)
has a degenerate lim0
0
0
b
b
iting distribution when Y1 (β0 X) = Y2 (θ0 W ) for all g1 (β0 X) ∈ Jz . Therefore, to obtain reasonable
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e ⊂ Ω
b such that for z ∈ Ω,
e Pn I{Yb1 (βb0 Xi ) 6=
interval estimators in practice, we consider the set Ω
i=1
P
n
Yb2 (θb0 Wi ), g1 (βb0 Xi ) ∈ Jz }/ i=1 I{g1 (βb0 Xi ) ∈ Jz } > d3 , where d3 is a given positive number. Then,
e a (1 − α), 0 < α < 1, point-wise confidence interval for ∆(z), is
for z ∈ Ω,
b
∆(z)
± ξα/2 σW ∗ (z) .

(2.12)

2
∗
Here, σW
∗ (z) is the variance of the random variable W (z). Moreover, a (1 − α) simultaneous confidence
e is
band for {∆(z), z ∈ Ω}
b
∆(z)
± τα σW ∗ (z) ,
(2.13)

where

¯ ∗
¯
©
ª
¯
¯
pr supz∈Ω
e W (z)/σW ∗ (z) < τα > 1 − α.

b = Ω.
e
Note that for the case with a continuous response Y, Ω
Now, since we use the entire data set to estimate the parameters in (2.1) and (2.4) and also to estib1 (·) and D
b2 (·) may be significantly underestimated.
mate the average prediction errors (2.3) and (2.6), D
To reduce such potential bias, one may consider the commonly used K-fold cross validation scheme.
Specifically, we randomly split the data into K disjoint subsets of about equal size and label them as
Ik , k = 1, · · · , K. For each k, we use all the observations, which are not in Ik , to estimate parameters in (2.1) and (2.4) via estimating functions (2.2) and (2.5), and then use the observations in Ik
to estimate prediction errors D1 (·) and D2 (·) with (2.8) and (2.9). Let the resulting estimators be deb1k (·) and D
b2k (·), respectively. The cross validated estimators for D1 (·), D2 (·) and ∆(·) are
noted by D
PK b
P
K
−1
e
e
e
b
e
e1 (·) = K −1
D
k=1 D2k (·) and ∆(·) = D1 (·) − D2 (·), respectively. Again,
k=1 D1k (·), D2 (·) = K
these estimators are uniformly consistent if K is relatively small with respect to n.
f1 (·) = n1/2 {D
e1 (·) −
In Appendix B, we show that for large n, the distributions of the processes W
1/2 e
1/2 e
f
f
D1 (·)}, W2 (·) = n {D2 (·) − D2 (·)} and W(·) = n {∆(·) − ∆(·)} can also be approximated well
by those of W1∗ (·), W2∗ (·) and W ∗ (·), respectively. Point-wise and simultaneous confidence intervals for
D1 (·), D2 (·), and ∆(·) can then be constructed based on the cross validated estimates and their large
sample distributions accordingly.
3. E XAMPLES
We use two examples to illustrate the new proposals. The first example is from a clinical trial conducted
by the AIDS Clinical Trials Group, ACTG 320 (Hammer and others, 1997). The study demonstrates that
for various response endpoints, on average the three-drug combination therapy consisting of indinarvir,
zidovudine and lamivudine, is much better than the two drug combination without indinarvir for treating
HIV infected patients. Unfortunately, even with this potent combination, some patients may not respond to
treatment, but suffer from non-trivial toxicity. Therefore, for future patients’ management, it is important
to have a reliable model for predicting patient’s treatment responses based on certain “baseline” markers.
A general conception is to use the baseline CD4 count and HIV-RNA, a measure of viral load, and the
early changes of these two markers after initiation of therapy for treatment guidance (Demeter and others,
2001). For resource-limited regions, however, the cost of obtaining HIV-RNA is relatively expensive.
Therefore, a challenging question is when we need RNA in addition to CD4 for better prediction of
patient’s response.
Recently Tian and others (2007) demonstrated that, on a population average sense, neither the baseline
nor early RNA change (from baseline to week 8) would add a clinically meaningful value for predicting
the long term change of CD4 (from baseline to Week 24), an important measure of the patient’s immune
response. Here, we try to locate a subgroup of patients, if any, who would benefit from the expensive
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marker RNA. To this end, let the response Y be the change of CD4 cell counts from Week 0 to 24, let U
consist of age, baseline CD4 and the early change in CD4, and let V consist of the baseline RNA and the
early change in RNA. For our analysis, in Models (2.1) and (2.4), we let X = (1, U 0 )0 , W = (1, U 0 , V 0 )0 ,
and g1 (·) and g2 (·) be the identity function. Also, we let Yb1 (β 0 X) = β 0 X, Yb2 (θ0 W ) = θ0 W , D(a, b) =
b = [15, 165]. In our analysis, we let d1 = d2 = 0.01
|a − b| and interval Jz be [z − 10, z + 10] for z ∈ Ω
b With n = 392 sets of complete observations of (Y, U, V ), the
discussed in Section 2 for choosing Ω.
regression parameter estimates for Models (2.1) and (2.4) are reported in Table 1. Note that the short term
changes of CD4 and RNA are statistically highly significant.

Table 1. Estimates of the regression parameters with their standard errors and corresponding p-values for testing zero
covariate effects for the AIDS example

Estimate
Std Error
P-value

Age
-0.55
0.35
0.12

Baseline RNA
0.08
5.53
0.99

RNA Change
-12.06
2.80
0.00

Baseline CD4
0.03
0.07
0.72

CD4 Change
0.68
0.10
0.00

For both working models, we utilized 5-fold cross validation scheme discussed in Section 2 to obtain
e1 (·), D
e2 (·), and ∆(·).
e
the regression parameters and then D
In Figure 1, we present these estimated prediction errors and their differences with the corresponding 0.95 point-wise and simultaneous confidence
e1 (z)} based on the model with age, baseline CD4 and
intervals given in (2.10)-(2.13). The values of {D
e2 (z)} based on the model with additional
early change in CD4 range from 37 to 74. The values of {D
e
RNA information range from 36 to 73. The estimated differences {∆(z)}
range from −1.7 to 6.0. These
indicate that there is no clinically meaningful gain from RNA for any subgroup of patients classified by
βb0 X. One may draw further statistical inference about the ∆(·). For example, for subjects whose score
e
g1 (βb0 X) ∈ Jz = [40, 60], the estimated ∆(50)
= 0.45 with 0.95 point-wise interval of (−3.25, 4.15) and
simultaneous interval of (−7.48, 8.38). Note that the results reported here are based on Jz with interval
length of 20, which is well within the intra-patient variation of CD4 measures. Various analyses have also
been done with Jz ’s whose lengths range from 30 to 60. All the results lead to the same conclusion. That
is, statistically or clinically, we cannot identify a subgroup of patients who would benefit from the extra
information of HIV-RNA for prediction of the long term CD4 change.
The data for the second example is from a population of patients screened for a clinical study, called
TRACE, for treating heart failure or acute myocardial infraction (MI) (Kober and others, 1995). There
were 6676 patients screened. Each patient had six routine clinical covariates: age, creatine (CRE), occurrence of heart failure (CHF), history of diabetes (DIA), history of hypertension (HYP), and cardiogenic
shock after MI (KS). Moreover, each patient had an echocardiographic assessment of left ventricular systolic function which was quantified by a measure called the wall motion index (WMI). Compared with
the above six covariates, the WMI is relatively expensive to obtain. Although not every screened patient
entered the clinical trial, all patients screened were followed closely for mortality.
Recently, Thune and others (2005) studied the prognostic importance of left ventricular systolic function in patients diagnosed with either heart failure or acute MI in addition to the patient’s medical history. It would be interesting to identify subpopulations that can benefit from the extra WMI measure
for predicting clinical outcomes such as mortality. Here, we let the outcome Y be a binary variable,
which is one if the patient died within five years. The five-year survival rate for this data set is approximately 42%. To evaluate the incremental value of WMI, we first fit the data using Model (2.1) with
X = (1, AGE, CRE, CHF, DIA, HYP, KS), and g1 (s) = exp(s)/{1 + exp(s)}. With the extra variable
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WMI, we fit a second logistic regression model with W = (X 0 , WMI)0 . A total of 5921 subjects have
complete predictor information. The estimates for the regression parameters with their standard errors are
reported in Table 2. Note that the WMI is highly statistically significant.
Table 2. Estimated Regression Coefficients for Model (2.1) with AGE, CRE, CHF, DIA, HYP, KS and WMI for the
screened population of TRACE study

Estimate
Std. Error
P-value

0.055
0.004
0.000

−0.010
0.002
0.000

0.759
0.067
0.000

0.718
0.101
0.000

0.187
0.073
0.010

1.153
0.163
0.000

−1.097
0.083
0.000

Next, we consider the prediction rules

and

Yb1 (β 0 X) = I{g1 (β 0 X) > c},

(3.1)

Yb2 (θ0 W ) = I{g2 (θ0 W ) > c}.

(3.2)

Moreover, let D(a, b) = |a − b|. Now, for c = 0.5, the 5-fold cross validated estimates obtained by letting
Jz be the entire real line in (2.8) and (2.9) for the overall prediction errors E[D(Y 0 , Yb1 (βb0 X 0 ))] and
E[D(Y 0 , Yb2 (βb0 W 0 ))] are 0.28 and 0.26, respectively, a modest overall incremental gain from the extra
information of WMI for the entire population of interest. To identify which subgroup of patients who
b = [0.15, 0.82]. Here, Ω
b is chosen by
would benefit with WMI, we let Jz = [z − 0.1, z + 0.1], for z ∈ Ω
letting d1 = d2 = 0.01 discussed in Section 2. To estimate Dl (z), l = 1, 2, and ∆(z), we used the 5-fold
e1 (·), D
e2 (·) and ∆(·).
e
cross validation to obtain D
In Figure 2, we present these point estimates and their
corresponding 0.95 point-wise and simultaneous confidence intervals. For the interval estimation, we let
e = [0.26, 0.76]. Note that the point estimates ∆(z)
e
b are not
d3 = 0.01. This results in Ω
for z outside Ω
e
b
e
reliable, and ∆(z) is pretty flat around 0 for z ∈ Ω− Ω, indicating that there is no evidence that WMI has a
e On the other hand, with the point and interval estimates displayed
meaningful gain outside the interval Ω.
in Figure 2(c), one may conclude that WMI is likely to be beneficial for patients with conventional risk
scores g1 (βb0 X) ranging from 0.16 to 0.74. If WMI is relatively affordable to the population of interest,
then one may consider using the upper bound of the simultaneous confidence intervals to identify the
b0
e
subpopulation based on ∆(z)+τ
α σW ∗ (z) > 0 and thus conclude that patients with g1 (β X) ∈ [0.16, 0.86]
are likely to benefit from the WMI. On the other hand, when WMI is not quite affordable, then one may
select the region conservatively and use the lower bound of the simultaneous confidence intervals based
e
on ∆(z)
− τα σW ∗ (z) > 0 and thus conclude that patients with g1 (βb0 X) ∈ [0.29, 0.63] are likely to benefit
from the WMI.
Note that for any prediction rule Yb , the conditional or unconditional expectation of the above distance
function D(Y, Yb ) consists of two discordance rates or two types of error rates. For example, D1 (z) in (2.3)
is D11 (z) + D10 (z), where D11 (z) = E[Y 0 D{1, Yb1 (β00 X 0 )}| g1 (β00 X 0 ) ∈ Jz ], the discordance rate for
false negative errors, and D10 (z) = E[(1 − Y 0 )D{0, Yb1 (β00 X 0 )}| g1 (β00 X 0 ) ∈ Jz ], the discordance rate
for false positive errors. The D20 (z) and D21 (z) are similarly defined. Let ∆0 (z) = D10 (z) − D20 (z)
and ∆1 (z) = D11 (z) − D21 (z). Oftentimes, a false negative conclusion may lead to a more serious
consequence than a false positive. Therefore, one may consider a weighted sum of ∆0 (z) and ∆1 (z),
∆(w, z) = w0 ∆0 (z) + w1 ∆1 (z), to evaluate the importance of the extra markers, where w = (w0 , w1 )0
e
and w0 and w1 are non-negative constants. For a given w, the cross validated point estimates ∆(w,
z) and
their interval estimates for ∆(w, z) can be constructed as for ∆(z) in Section 2.
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In Figure 3(a),(b),(c) and (d), we present the point and interval estimates of ∆(w, z) for the predictors
(3.1) and (3.2) with c = 0.5 and various choices of w. Note that when w0 6= w1 , even if the working model
is correctly specified, the prediction rule in (3.1) or (3.2) with c = 0.5 is not optimal with respect to the
weighted error rate. Furthermore, with the unequal weighting criterion, for some subgroups of patients,
inclusion of the extra information of WMI may significantly decrease the prediction precision.
For a given w, with the weighted sum prediction precision measure, w0 D10 (z) + w1 D11 (z), it is
straightforward to show that the optimal prediction rule based on X that minimizes the above criterion
is Yb = I{pr(Y = 1 | X) > cw }, where cw = w0 /(w0 + w1 ). Therefore, for the present example, if
g1 (βb0 X) and g2 (θb0 W ) are reasonably good approximations to E(Y |U ) and E(Y |U, V ), the predictors
I(g1 (βb0 X) > cw ) and I(g2 (θb0 W ) > cw ) are almost optimal. In Figure 4, we present the cross validated
point estimates along with the 0.95 interval estimates of ∆(w, z) with w = (1, 4)0 and (1, 9)0 when
“optimal” prediction rules are used for both models. It appears that there is minimal gain from WMI
across all sub-populations indexed by g(βb0 X) ∈ Jz for both cases.
4. R EMARKS
From the results of our analysis presented in the Example Section, we find that the decision to include
or exclude the additional biomarkers for prediction of a patients’ health outcome depends heavily on the
prediction precision measure or utility function. In the cardiovascular disease arena, clinicians may recommend certain treatments to patients whose predicted 10-year risk of having a cardiovascular event is
higher than, for example, 10%. The utility or cost function for choosing this cutoff points can be rather
complex, if not impossible, to quantify. Furthermore, the utility function may vary across individuals and
hence different patients may have different optimal cutoff points for predicting patient-level outcomes.
The weighted sum of prediction error rates presented in this article is an attempt to cope with this complicated cost-benefit issue. The complexities of choosing a loss function extend to the case of continuous
responses. For example, weighting absolute prediction errors according to the observed response may lead
to a more meaningful penalty in some cases than the un-weighted absolute prediction error.
The proposed methods may be extended to the case where responses are event times subjected to
censoring. Since the support of the censoring variable is usually shorter than that of the event time in
practice, we may utilize the approach taken by Uno and others (2007) and construct predictors for t-year
survival. It would be interesting to investigate whether the additional biomarkers are useful for predicting
long- or short-term survivors, with potentially different subsets of patients benefiting in each case.
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6. APPENDIX A
b1 (·), D
b2 (·) and ∆(·)
b
Large sample properties of D
To justify the asymptotic properties of the proposed estimators, certain smooth regularity conditions
are needed for the distance function D(·, ·) and its corresponding predictor. Here, we consider the case that
(1−Y ) Y
the distance function is D(Y, Yb ) = |Y − Yb | for continuous and w0
w1 |Y − Yb | for binary responses,
where w0 and w1 are given positive numbers. Furthermore, when Y is continuous, we let Yb1 (β 0 x) =
g1 (β 0 x), and Yb2 (θ0 w) = g2 (θ0 w), and when Y is binary, let Yb1 (β 0 x) = I{g1 (β 0 x) > constant}, and
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Yb2 (θ0 w) = I{g2 (θ0 w) > constant}. Similar arguments can be used to justify other cases.
Suppose that β0 and θ0 are interior points of their compact parameter spaces. Let Ω denote the set of
z such that Jz is properly contained in the support of β00 X. First, we show that the above estimators are
b = (βb0 , θb0 )0 and Θ = (β 0 , θ0 )0
uniformly consistent over Ω. To this end, let Θ
b1 (z, β) =
D

b2 (z, Θ) =
D

Pn
i=1

Pn
i=1

D{Yi , Yb1 (β 0 Xi )}I{g1 (β 0 Xi ) ∈ Jz }
Pn
,
0
i=1 I{g1 (β Xi ) ∈ Jz }

D{Yi , Yb2 (Wi , θ)}I{g1 (β 0 Xi ) ∈ Jz }
Pn
,
0
i=1 I{g1 (β Xi ) ∈ Jz }

D1 (z, β) = E[D{Y, Yb1 (β 0 X)}|g1 (β 0 X) ∈ Jz ] and D2 (z, Θ) = E[D{Y, Yb2 (θ0 W )}|g1 (β 0 X) ∈ Jz ]. It
b1 (z, β) − D1 (z, β)| +
follows from the uniform law of large numbers (Pollard, 1990, Ch. 8) that supz,β |D
b2 (z, Θ) − D2 (z, Θ)| converges to 0, in probability, where the sup is taken over Ω and the pasupz,Θ |D
b implies the uniform consistency
rameter spaces. This, together with the convergence property of βb and θ,
b
b1 (z) = D
b1 (z, β) and D
b2 (z) = D
b2 (z, Θ).
b The consistency of ∆(·)
b follows accordingly.
of D
b1 (·), D
b2 (·) and ∆(·)
b after standardization are asymptotically norNext, we show that the processes D
b = (βb0 , θb0 )0 . It follows from Appendix 1 of Tian and others (2007),
mal. First, let T = (Y, U 0 , V 0 )0 and Θ
1 Pn
1
−
b
n 2 (Θ − Θ0 ) = n 2 i=1 ψ(Ti ) + op (1), where ψ(T ) = {ψ1 (T )0 , ψ2 (T )0 }0 ,
ψ1 (T ) = [E{ġ1 (β00 X)XX 0 }]−1 X{Y − g1 (β00 X)}, ψ2 (T ) = [E{ġ2 (θ00 W )W W 0 }]−1 W {Y − g2 (θ00 W )},
n
o
b1 (z, β) − D1 (z, β) and W
c1 (z, β) = n 12 D
c2 (z, Θ) =
and ġk (·) is the derivative of gk (·). Now, let W
o
n
1
b2 (z, Θ) − D2 (z, Θ) . By the maximum inequality for the standard empirical processes (Pollard,
n2 D
1990, Ch.9),
¯
¯
¯
¯
n
n
¯
¯
¯
¯
X
X
¯c
¯
¯
¯c
− 12
− 12
ξ1 (z, β, Ti )¯ + sup ¯W2 (z, Θ) − n
ξ2 (z, Θ, Ti )¯ → 0,
sup ¯W1 (z, β) − n
¯ z,Θ ¯
¯
z,β ¯
i=1

i=1

in probability, as n → ∞, where

ξ1 (z, β, Ti ) =

h
i
I{g1 (β 0 Xi ) ∈ Jz } D{Yi , Yb1 (β 0 Xi )} − D1 (z, β)
pr(g1 (β 0 X) ∈ Jz )

,

and

ξ2 (z, Θ, Ti ) =

h
i
I{g1 (β 0 Xi ) ∈ Jz } D{Yi , Yb2 (Wi , θ)} − D2 (z, Θ)
pr(g1 (β 0 X) ∈ Jz )

.
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1
b − Θ0 ), implies that
This, together with the above linear expansion of n 2 (Θ
n
o
b − D1 (z, β)
b + D1 (z, β)
b − D1 (z, β0 )
b1 (z, β)
c1 (z) = n 21 D
W
o
n
1
b1 (z, β0 ) − D1 (z, β0 ) + Ḋ(2) (z, β0 )0 n 12 (βb − β0 )
' n2 D
1
1

' n− 2

n n
o
X
(2)
ξ1 (z, β0 , Ti ) + Ḋ1 (z, β0 )0 ψ1 (Ti )

(6.1)

i=1

c2 (z) = n 21
W

n
o
b2 (z, Θ)
b − D2 (z, Θ)
b + D2 (z, Θ)
b − D2 (z, Θ0 )
D
1

' n− 2

n n
o
X
(2)
ξ2 (z, Θ0 , Ti ) + Ḋ2 (z, Θ0 )0 ψ(Ti )

(6.2)

i=1
(2)

(2)

where Ḋ1 (z, β) = ∂D1 (z, β)/∂β and Ḋ2 (z, Θ) = ∂D2 (z, Θ)/∂Θ. It follows from a functional central
c1 (·) and W
c2 (·) converge weakly to zero-mean
limit theorem (Pollard, 1990, Ch. 10) that the processes W
c
Gaussian processes. The weak convergence of W(·) follows accordingly.
c1 (·), W
c2 (·) and W(·),
c
To approximate the distribution of the processes W
we consider the perturbed
version of these processes. The resulting processes are
)
(P
n
b
b −D
b1 (z, β)]I{g(
βb0 Xi ) ∈ Jz }Gi
[D{Yi , Yb1 (Xi , β)}
1
∗
∗
i=1
b ,
b1 (z, βb ) − D
b1 (z, β)
+D
W1 (z) = n 2
Pn
b0
i=1 I{g(β Xi ) ∈ Jz }
(6.3)
)
(P
n
0
b −D
b2 (z, Θ)]I{g(
b
βb Xi ) ∈ Jz }Gi
[D{Yi , Yb2 (Wi , θ)}
1
∗
∗
i=1
b
b
b
b
W2 (z) = n 2
+ D2 (z, Θ ) − D2 (z, Θ) ,
Pn
b0
i=1 I{g(β Xi ) ∈ Jz }
(6.4)
and
W ∗ (z) = W1∗ (z) − W2∗ (z),

(6.5)

where {G1 , ..., Gn } are independent standard normal random variables that are independent of the data,
b ∗ = (βb∗0 , θb∗0 )0 ,
Θ
( n
)−1 n
o
X n
X
∗
0
0
βb = βb +
ġ1 (βb Xi )Xi X
Xi Yi − g1 (βb0 Xi ) Gi
i

(
and

θb∗ = θb +

i=1
n
X

)−1
ġ2 (θb0 Wi )Wi Wi0

i=1

i=1
n
X

n
o
Wi Yi − g2 (θb0 Wi ) Gi .

i=1

It follows from the same arguments as given above and similar arguments as in Appendix 4 of Cai and
others (2005) that the limiting distributions of W1∗ (·), W2∗ (·) and W ∗ (·), conditional on the data, are
c1 (·), W
c2 (·) and W(·),
c
b ⊂ Ω) → 1, the confithe same as those of W
respectively, on Ω. Since pr(Ω
b Furthermore, noting the fact that
dence interval given in (2.10)is asymptotically valid for any z ∈ Ω.
∗
c
∗
supΩ
|W
(z)/σ
|
and
sup
|
W
(z)/σ
|
are
asymptotically
equivalent
to supΩd1 ,d2 |Wl∗ (z)/σWl∗ (z) |
l
b
b
Wl (z)
cl (z)
l
Ω
W
cl (z)/σ c |, respectively, where Ωd ,d ⊂ Ω is the limit of Ω,
b the asymptotical conand supΩ
|W
d1 ,d2

Wl (z)

1

2

b given in (2.11) is valid as well. Similarly, one may justify the
fidence band over the random region Ω
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e d , the limit of Ω,
e
validity of the confidence interval and band given in (2.12) and (2.13) by noting that Ω
3
e
is a subset of Ω and σW(z) is uniformly bounded below by a positive constant for z ∈ Ω.
7. APPENDIX B
Large sample properties of crossvalidated estimators
b (−k) = (βb0 , θb0 )0 be the estimated Θ using data not in Ik via (2.2)
For each partition Ik , let Θ
(−k) (−k)
and (2.5),
P
D{Yi , Yb1 (β 0 Xi )}I{g1 (β 0 Xi ) ∈ Jz }
b
D1k (z, β) = i∈Ik P
,
0
i∈Ik I{g1 (β Xi ) ∈ Jz }
and
P
b2k (z, Θ) =
D

i∈Ik

D{Yi , Yb2 (θ0 Wi )}I{g1 (β 0 Xi ) ∈ Jz }
P
.
0
i∈Ik I{g1 (β Xi ) ∈ Jz }

b 1k (z, βb(−k) ) is consistent. Then, it follows from the same argument
Since K is small with respect to n, D
b 1k (z, βb(−k) ) − D1 (z, β0 )} is asymptotically equivalent to
in Appendix A, n1/2 {D
1

n− 2 K

n
X

1
I(τi = k)ξ1 (z, β0 , Ti ) + n 2 Ḋ1 (z, β0 )(βb(−k) − β0 ),

i=1

where {τi ; i = 1, · · · , n} are P
n exchangeable discrete random variables uniformly distributed over {1, 2, · · · , K},
n
independent of the data, and i=1 I(τi = k) ≈ n/K, k = 1, · · · , K. It follows from the same argument
in Appendix 3 of Tian and others (2007) that conditional on the observed {τi , i = 1, · · · , n}
βb(−k) − β0 =

n

X
K
I(τi 6= k)ψ1 (Ti ) + op (n−1/2 ).
n(K − 1) i=1

Then using the same argument in Appendix A, one can show that
¾
1
K
n X
K ½
o n− 21 X
n2 X n e
KI(τi 6= k)ψ1 (Ti )
f
W1 (z) =
D1k (z) − D1 (z) =
I(τi = k)Kξ1 (z, β0 , Ti ) +
.
K
K i=1
K −1
k=1

PK

k=1

PK

f1 (z)
Since k=1 I(τi = k) = 1 and k=1 I(τi 6= k) = K − 1, it is straightforward to show that W
c1 (z) and thus the distribution of W
f1 (·) can be approximated by that of
is asymptotically equivalent to W
W1∗ (·) conditional on the partition indicators {τi , i = 1, · · · , n}. Similar arguments can be used to show
f2 (·) and W(·)
f can be approximated by those of W ∗ (·) and W ∗ (·), respectively.
that the distributions of W
2
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Fig. 1. Point estimates for D1 (·), D2 (·) and ∆(·) with corresponding 0.95 point-wise (dashed lines) and simultaneous
(shaded regions) confidence intervals for the HIV example.

50

100

150

150
100
50
0

Absolute Prediction Error

(a) D1 (z), without HIV-RNA

50

100

150

10 20 30
−10 0
−30

Reduction of Error

(b) D2 (z), with HIV-RNA

50

100

150

z

(c) ∆(z)

http://biostats.bepress.com/harvardbiostat/paper64

Identifying patients who need additional biomarkers for better prediction of clinical phenotype

15

1.0
0.8
0.6
0.4
0.2
0.0

Absolute Prediction Error

Fig. 2. Point estimates for D1 (·), D2 (·) and ∆(·) with corresponding 0.95 point-wise (dashed lines) and simultaneous
(shaded regions) confidence intervals for the screened population of the TRACE study (the prediction with c = 0.5).
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Fig. 3. Point estimate ∆(w,
·) for ∆(w, ·) with various weights and the corresponding 0.95 point-wise (dashed lines)
and simultaneous (shaded regions) confidence intervals for the screened population of the TRACE study (the prediction with c = 0.5).
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Fig. 4. Point estimate ∆(w,
·) for ∆(w, ·) with the ”optimal” weights and the corresponding 0.95 point-wise (dashed
lines) and simultaneous (shaded regions) confidence intervals for the screened population of the TRACE study.

0.2

0.3

0.4

0.5

0.6

0.7

0.8

0.7

0.8

0.10
0.00
−0.10

Reduction of Error

0.20

(a) w0 = 1, w1 = 4, c = 0.2

0.2

0.3

0.4

0.5

0.6

z
(b) w0 = 1, w1 = 9, c = 0.1

Hosted by The Berkeley Electronic Press

